DIA 2020 Global Annual Meeting

Safety for subjects participating in clinical trials is paramount. Regulatory reporting requirements that are in place around the world facilitate the timely notification of regulatory authorities, sponsors, investigators and ethics committees to ensure that that emerging risks are identified swiftly and that trial subjects are protected. Once a product is granted authorization, pharmacovigilance requirements apply to ensure patients are protected and, if interventional studies are ongoing, clinical trials requirements continue to apply to ensure protection for trial subjects. This session will look at novel approaches to efficiently fulfilling safety reporting requirements for clinical trials. The session will also examine the interfaces between pharmacovigilance and clinical trials, and how strong relationships between pharmacovigilance and clinical functions can achieve a more proactive approach to protecting both patients and trial subjects.